Drug and disease signature integration identifies synergistic combinations in glioblastoma von Stathias, Vasileios, Jermakowicz, Anna M., Maloof, Marie E., Forlin, Michele, Walters, Winston, Suter, Robert K., Durante, Michael A., Williams, Sion L., Harbour, J. William, Volmar, Claude-Henry, Lyons, Nicholas J., Wahlestedt, Claes, Graham, Regina M., Ivan, Michael E., Komotar, Ricardo J., Sarkaria, Jann N., Subramanian, Aravind, Golub, Todd R., Schürer, Stephan C., Ayad, Nagi G.

Volltext

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion von Jermakowicz, Anna M., Rybin, Matthew J., Suter, Robert K., Sarkaria, Jann N., Zeier, Zane, Feng, Yangbo, Ayad, Nagi G.

Volltext

RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma von Jermakowicz, Anna M., Kurimchak, Alison M., Johnson, Katherine J., Bourgain-Guglielmetti, Florence, Kaeppeli, Simon, Affer, Maurizio, Pradhyumnan, Hari, Suter, Robert K., Walters, Winston, Cepero, Maria, Duncan, James S., Ayad, Nagi G.

Volltext

Drug Repositioning in Glioblastoma: A Pathway Perspective von Tan, Sze Kiat, Jermakowicz, Anna, Mookhtiar, Adnan K, Nemeroff, Charles B, Schürer, Stephan C, Ayad, Nagi G

Volltext

337 Targeting metabolic and epigenetic programs to re-sensitize glioblastoma to chemotherapy von Rowland, Emma, Walter, Thomas, Suter, Robert, Jermakowicz, Anna, Riggins, Rebecca, Ayad, Nagi

Volltext

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis von Greenblatt, Sarah M., Man, Na, Hamard, Pierre-Jacques, Asai, Takashi, Karl, Daniel, Martinez, Concepcion, Bilbao, Daniel, Stathias, Vasileios, Jermakowicz, Anna M., Duffort, Stephanie, Tadi, Madhavi, Blumenthal, Ezra, Newman, Samantha, Vu, Ly, Xu, Ye, Liu, Fan, Schurer, Stephan C., McCabe, Michael T., Kruger, Ryan G., Xu, Mingjiang, Yang, Feng-Chun, Tenen, Daniel G., Watts, Justin, Vega, Francisco, Nimer, Stephen D.

Volltext

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis von Greenblatt, Sarah M., Man, Na, Hamard, Pierre-Jacques, Asai, Takashi, Karl, Daniel, Martinez, Concepcion, Bilbao, Daniel, Stathias, Vasileios, Jermakowicz, Anna M., Duffort, Stephanie, Tadi, Madhavi, Blumenthal, Ezra, Newman, Samantha, Vu, Ly, Xu, Ye, Liu, Fan, Schurer, Stephan C., McCabe, Michael T., Kruger, Ryan G., Xu, Mingjiang, Yang, Feng-Chun, Tenen, Daniel G., Watts, Justin, Vega, Francisco, Nimer, Stephen D.

Volltext

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS von Jermakowicz, Anna, Suter, Robert, Ruiz, Luz, Ayad, Nagi

Volltext

DDDR-23. IN SILICO DRUG DISCOVERY REVEALS SUBTYPE-SPECIFIC COMBINATION THERAPIES WITH CASEIN KINASE 2 INHIBITOR CX-4945 IN GLIOBLASTOMA von Ayad, Nagi, Suter, Robert, Jermakowicz, Anna, Kaeppeli, Simon

Volltext

BSCI-23 ANEUPLOIDY PROFILING IN GLIOBLASTOMA IDENTIFIES MECHANISMS OF DISEASE PROGRESSION AND TREATMENT VULNERABILITIES von Jermakowicz, Anna, Stukenberg, P Todd, Ayad, Nagi

Volltext

Glutaminase 2 as a therapeutic target in glioblastoma von Veeramachaneni, Rithvik K., Suter, Robert K., Rowland, Emma, Jermakowicz, Anna, Ayad, Nagi G.

Volltext

COMP-16. COMPREHENSIVE TRANSCRIPTOMIC ANALYSIS OF SINGLE CELLS FROM RECURRENT AND PRIMARY GLIOBLASTOMA TO PREDICT CELL-TYPE SPECIFIC THERAPEUTICS von Suter, Robert, Stathias, Vasileios, Jermakowicz, Anna, Semonche, Alexa, Ivan, Michael, Komotar, Ricardo, Schürer, Stephan, Ayad, Nagi

Volltext

GENE-36. INTEGRATING TRANSCRIPTOMICS AND KINOMICS IDENTIFIES SYNERGISTIC DRUG COMBINATIONS FOR GLIOBLASTOMA TREATMENT von Jermakowicz, Anna, Stathias, Vasileios, Suter, Robert, Duncan, James, Schürer, Stephan, Ayad, Nagi

Volltext

EPCO-18. A MESENCHYMAL CELL POPULATION MEDIATES RESISTANCE TO AURORA KINASE INHIBITORS IN GLIOBLASTOMA von Suter, Robert, Stathias, Vasileios, Jermakowicz, Anna, Pradhyumnan, Hari, Affer, Maurizio, Guglielmetti, Florence, Ivan, Michael, Komotar, Ricardo, de la Fuente, Macarena, Sarkaria, Jann, Schürer, Stephan, Ayad, Nagi

Volltext

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models von Rodriguez-Blanco, Jezabel, Salvador, April D, Suter, Robert K, Swiderska-Syn, Marzena, Palomo-Caturla, Isabel, Kliebe, Valentin, Shahani, Pritika, Peterson, Kendell, Turos-Cabal, Maria, Vieira, Megan E, Wynn, Daniel T, Howell, Ashley J, Yang, Fan, Ban, Yuguang, McCrea, Heather J, Zindy, Frederique, Danis, Etienne, Vibhakar, Rajeev, Jermakowicz, Anna, Martin, Vanesa, Coss, Christopher C, Harris, Brent T, de Cubas, Aguirre, Chen, X Steven, Barnoud, Thibaut, Roussel, Martine F, Ayad, Nagi G, Robbins, David J

Volltext

EPCO-14. ISOSCELES: AN INTEGRATIVE FRAMEWORK FOR THE PREDICTION OF TREATMENT RESISTANT GLIOBLASTOMA CELLS von Suter, Robert, Jermakowicz, Anna, Stathias, Vasileios, Ruiz, Luz, D'Antuono, Matthew, Kaeppeli, Simon, Baker, Grace, Veeramachaneni, Rithvik, Walters, Winston, Cepero, Maria, Williams, Sion, Ivan, Michael, Komotar, Ricardo, De La Fuente, Macarena, Sarkaria, Jann, Schürer, Stephan, Ayad, Nagi

Volltext

Abstract 1747: Targeting metabolic and epigenetic programs to re-sensitize glioblastoma to chemotherapy von Rowland, Emma, Walter, Jordan, Jermakowicz, Anna, Suter, Robert, Riggins, Rebecca, Ayad, Nagi

Volltext

Drug and disease signature integration identifies synergistic combinations in glioblastoma von Jermakowicz, Anna

Volltext bestellen

Drug and disease signature integration identifies synergistic combinations in glioblastoma von Jermakowicz, Anna

Volltext bestellen

Catalytic reductions of nitroaromatic compounds over heterogeneous catalysts with rhenium sub-nanostructures von Cyganowski, Piotr, Dzimitrowicz, Anna, Marzec, Mateusz M., Arabasz, Sebastian, Sokołowski, Krystian, Lesniewicz, Anna, Nowak, Sylwia, Pohl, Pawel, Bernasik, Andrzej, Jermakowicz-Bartkowiak, Dorota

Volltext